The incidence of urolithiasis (kidney/renal stones) depends on geographic, climatic, ethnic, dietary, and genetic factors. Assistant Professor Chua Wei Jin, Senior Consultant, Department of Urology at the National University Hospital in Singapore discusses with Audrey Abella why urolithiasis is an important healthcare problem that requires attention.
Lung Cancer Network Malaysia (LCNM), a newly minted non-governmental organization seeks to improve lung cancer awareness in the country. Founders Dr Anand Sachithanandan, a consultant cardiothoracic surgeon, and Dr Tho Lye Mun, a consultant clinical oncologist, sat down with MIMS Doctor to talk about their aspirations for the society and their hopes with regards to lung cancer treatment.
MIMS reports on excepts from a recent dialogue on ‘The Leading Edge of Health Coaching: Empowering Patients in the Myriad of Daily Health Decisions’ at the recent Malaysian Innovative Healthcare Symposium (MIHS) 2019.
Nasopharyngeal cancer (NPC) is a disease in which cancer cells develop from the tissues of the nasopharynx – an area located behind the nose, just above the back of the throat. Chinese from endemic regions such as Hong Kong and Southern China have the highest risk of getting NPC. NPC is the ninth most common cancer among men in Singapore with the highest incidence in Chinese followed by Malays and is rare among Indians. [Singapore Cancer Registry Annual Registry Report, Trends in Cancer Incidence in Singapore 2015]
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 20190807035449
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
Individuals with hearing disabilities often have issues with healthcare access due to communication gaps between them and medical staff. At the recent Beyond Dispensing: Malaysian Medical Sign Language 2019 workshop jointly organized by the Malaysian Community Pharmacy Business Forum (MyCPBF), the Malaysian Sign Language and Deaf Studies Association (MyBIM), The Light and the Malaysian Federation for the Deaf (MFD), a group of healthcare professionals took some time off to learn how to bridge the gaps.
Dr Andrew Ong, a consultant at the Department of Gastroenterology & Hepatology, Singapore General Hospital, explains to Roshini Claire Anthony the challenges in diagnosing and treating irritable bowel syndrome (IBS).
How does it feel to be told one has contracted HIV? How equipped are doctors when breaking the news to a patient that he or she has been diagnosed with HIV? Are we able to provide people living with HIV (PLHIV) the counselling and skills required to take them through this difficult period of life? MIMS Doctor speaks to Dr Julian Hong, a general physician practicing in Singapore, about the challenges faced by both patients and doctors when faced with the difficult topic of HIV.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.